NCIt definition : An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone
deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor JNJ-26481585
inhibits HDAC leading to an accumulation of highly acetylated histones, which may
result in an induction of chromatin remodeling; inhibition of the transcription of
tumor suppressor genes; inhibition of tumor cell division; and the induction of tumor
cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin
histone proteins. Compared to some first generation HDAC inhibitors, JNJ-26481585
may induce superior HSP70 upregulation and bcl-2 downregulation.;
UNII : 9BJ85K1J8S;
InChIKey : PAWIYAYFNXQGAP-UHFFFAOYSA-N;
CAS number : 875320-29-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 875320-29-9
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;